Core Insights - Klotho Neuroscience, Inc. is partnering with leading researchers from the Okinawa Research Center for Longevity Science to explore the role of the Klotho gene in promoting longevity and reducing neurodegenerative diseases [1][2][3] Company Overview - Klotho Neuroscience, Inc. (NASDAQ: KLTO) focuses on developing cell and gene therapies targeting neurological conditions such as ALS, Alzheimer's Disease, and Parkinson's Disease [1][4] - The company utilizes a patented form of the Klotho gene, specifically the secreted alpha-Klotho protein isoform (s-KL), in its innovative therapies [4] Research and Development - Preliminary data from ORCLS suggests that the alpha-Klotho gene and its protein isoform may contribute to healthy longevity, with decreased levels correlating with various age-related diseases [2][3] - The partnership will analyze blood samples from centenarians to assess the Klotho protein's role in longevity and its potential protective effects against neurodegenerative disorders [3][4] Historical Context - Okinawa is recognized as the original Blue Zone, known for its high concentration of centenarians, validated by extensive research from ORCLS over the past five decades [2][3] - ORCLS has a history of significant discoveries in human aging, including the identification of longevity genes and their translation from model organisms to humans [3]
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population